<p>
<strong><u>Release Date</u></strong><br/>
January 23, 2015<br/><br/>
<strong><u>Expiration Date</u></strong><br/>
January 23, 2016<br/><br/>

<strong><u>Faculty</u></strong><br/>
Chiara Cremolini, MD <br>
University of Pisa <br>
Pisa, Italy <br>
<br><br>
George D. Demetri, MD<br>
Dana-Farber Cancer Institute<br>
Boston, Massachusetts<br>
<br><br>
Axel Grothey, MD<br>
Mayo Clinic<br>
Rochester, Minnesota<br>
<br><br>
David Ilson, MD, PhD<br>
Memorial Sloan Kettering Cancer Center<br>
New York, New York<br>
<br><br>
Kimmie Ng, MD, MPH<br>
Dana-Farber Cancer Institute<br>
Boston, Massachusetts<br>
<br><br>
Daniel H. Palmer, MD<br>
University of Liverpool<br>
Liverpool, United Kingdom<br>
<br><br>
Marc Peeters, MD, PhD<br>
Antwerp University Hospital<br>
Antwerp, Belgium<br>
<br><br>
Fernando Rivera, MD, PhD<br>
Marqués de Valdecilla University Hospital<br>
Santander, Spain<br>
<br><br>
Binay K. Shah, MBBS, MD<br>
St Joseph Cancer Center<br>
Lewiston, Idaho<br>
<br><br>
Salvatore Siena, MD<br>
Niguarda Cancer Center<br>
Milan, Italy<br>
<br><br>
Sebastian Stintzing, MD<br>
University of Munich<br>
Munich, Germany<br>
<br><br>
Melanie B. Thomas, MD<br>
Medical University of South Carolina<br>
Charleston, South Carolina<br>
<br><br>
Gianluca Tomasello, MD<br>
Azienda Istituti Ospitalieri di Cremona<br>
Cremona, Italy<br>
<br><br>
Andrew X. Zhu, MD, PhD<br>
Massachusetts General Hospital<br>
Boston, Massachusetts<br>

<strong><u>Learning Objectives:</u></strong><br/>
After successful completion of  this educational activity, participants should be able to:
<ul class="bullets">
  <li>Integrate recent clinical trial data and emerging therapeutic strategies into the management of mCRC in the first-line setting and for progressive disease </li>
  <li>Evaluate recently approved and emerging therapies with the potential to improve outcomes for patients with gastric cancer, including targeted agents and immunotherapies</li>
  <li>Apply recent data when devising optimal treatment plans for patients with pancreatic cancer</li>
  <li>Employ best practices when treating patients with gastrointestinal stromal tumors (GIST) based on current treatment guidelines and recent clinical trial data</li>
</ul>
<br/>

<strong><u>Providership</u></strong><br/>
This activity is provided by prIME Oncology.<br/><br/>

<strong><u>Support</u></strong><br/>
This educational activity is supported by grants from Bayer HealthCare Pharmaceuticals and Lilly.<br/><br/>

<strong><u>Target Audience</u></strong><br/>
This activity is intended to meet the needs of practicing medical oncologists, surgical and radiation oncologists, gastroenterologists, and other healthcare professionals involved in the treatment of patients with gastrointestinal cancer.  <br/><br/>

<strong><u>Continuing Medical Education</u></strong><br/>
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.<br/><br/>
prIME Oncology designates this enduring activity for a maximum of X.XX <em>AMA PRA Category 1 Credits<sup>&trade;</sup></em>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.<br/><br/>

<strong><u>Method of Participation</u></strong><br/>
There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology's database. However, upon request, your CME credit certificate will be emailed to you.<br><br>

Technical requirements may be found under the&nbsp;<a href="http://www.primeoncology.org/footer-e-pages/terms_of_use.aspx">Terms  of Use</a>.<br><br>

Links to the posttest are available on the video player pages.<br/><br/>

In order to receive credit, participants must successfully complete the online posttest with 80 % or higher.<br/><br/>

<strong><u>Disclosure of Relevant Financial Relationships</u></strong><br/>
prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.<br/><br/>

<strong><u>Faculty Disclosures</u></strong><br/>
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:<br/><br/>

Dr Cremolini has disclosed that she has received consulting fees from Bayer and Roche. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.<br><br>

Dr Demetri has disclosed that he has received consulting fees from Ariad, Astra-Zeneca, Bayer, Bessor Pharmaceuticals (uncompensated), Bind Therapeutics, Blueprint Medicines (scientific advisory board), Caris (scientific advisory board), Champions Oncology (scientific advisory board), Daiichi-Sankyo, EMD-Serono, G1 Therapeutics (scientific advisory board), Glaxo-Smith-Kline, Janssen Oncology, Kolltan Pharmaceuticals (scientific advisory board), Pfizer, Polaris Pharmaceuticals, Sanofi Oncology, WIRB Copernicus Group, and ZioPharm. He has also performed contracted research support for Dana-Farber for specific clinical trial agreements in the sarcoma unit for Bayer, EMD-Serono, Glaxo-Smith-Kline, Janssen Oncology, Novartis, Pfizer, and Sanofi Oncology. He has equity minor stake, non-public in , Bessor Pharmaceuticals Blueprint Medicines, Champions Oncology, G1 Therapeutics, and Kolltan Pharmaceuticals. He has equity minor stake, public in Caris. He has received royalties paid to Dana-Farber and patent licensed to Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.<br><br>

Dr Grothey has disclosed that he has performed contracted research for Bayer, Eisai, Eli-Lilly, Genentech, and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation. <br><br>

Dr Ilson has disclosed that he has received consulting fees from Amgen, Bayer, and Lilly. He has also performed contracted research for Amgen, Bayer, and Bristol-Myers Squibb. He has received fees for non-CME services from Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation. <br><br>

Dr Ng has disclosed that she has received consulting fees from Genentech, Inc. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.  <br><br>

Dr Palmer has disclosed that he has received consulting fees from Bayer and Boehringer Ingelheim. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation. <br><br>

Dr Peeters has disclosed that he has received fees for non-CME services from Amgen. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation. <br><br>

Dr Rivera has disclosed that he has received consulting fees from Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation. <br><br>

Dr Shah has disclosed that he has stocks in Gilead and Pfizer. He has received fees for speaking  for Teva. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation. <br><br>

Dr Siena has disclosed that he has received consulting fees from Amgen, Bayer, Ignyta Pharmaceuticals, Roche, and Sanofi. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation. <br><br>

Dr Stintzing has disclosed that he has received consulting fees from Amgen, Bayer, Genentech, Merck Serono, Roche, and Sanofi. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation. <br><br>

Dr Thomas has no relevant financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation. <br><br>

Dr Tomasello has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation. <br><br>

Dr Zhu has disclosed that he has received consulting fees from Celgene, Eisai, Exelixis, and Sanofi-Aventis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation. <br><br>

The employees of prIME Oncology have disclosed:</p>
<ul class="bullets">
  <li>Chelsey Goins, PhD (clinical content reviewer/planner) - no relevant financial relationships</li>
  <li>Sanneke Koekkoek, BSN, OCN (clinical content reviewer/planner) – no relevant financial relationships</li>
  <li>Christi Gray (editorial content reviewer) – no relevant financial relationships </li>
</ul>

<p><br/>
<strong><u>Disclosure Regarding Unlabeled Use</u></strong><br/>
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.<br/><br/>

<strong><u>Disclaimer</u></strong><br/>
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.<br/>
</p>